NYSE:TEVAPharmaceuticals
Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive long term results from the RELIEVE UCCD extension study of duvakitug in ulcerative colitis and Crohn’s disease.
The TL1A antibody maintained efficacy and safety over 44 weeks in patients with inflammatory bowel disease.
The partners plan to advance duvakitug into phase III trials, targeting a potential best in class therapy in this treatment area.
For you as an investor following NYSE:TEVA, this update sits at the...